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Objectives This study sought to compare the effects of metoprolol and carvedilol in the MADIT-CRT (Multicenter Automatic
Defibrillator Implantation Trial With Cardiac Resynchronization Therapy) study.
Background The impact of beta-blockers in heart failure (HF) patients with devices is uninvestigated.
Methods All patients receiving either metoprolol or carvedilol in the MADIT-CRT study were identified and compared.
Time-dependent Cox proportional hazard regression analyses were performed to assess differences in hospital-
ization for HF or death and ventricular arrhythmias.
Results Hospitalization for HF or death occurred in 30% of the patients on metoprolol and in 23% on carvedilol. Treat-
ment with carvedilol was associated with a significantly decreased risk of hospitalization for HF or death when
compared with metoprolol (hazard ratio [HR]: 0.70, [95% confidence interval (CI): 0.57 to 0.87], p  0.001).
This reduction in risk was further attenuated in the subgroup of cardiac resynchronization therapy with implant-
able cardioverter-defibrillator (CRT-D) patients (HR: 0.61 [95% CI: 0.46 to 0.82], p  0.001) and CRT-D patients
with left bundle branch block (LBBB) (HR: 0.51 [95% CI: 0.35 to 0.76], p  0.001). Ventricular arrhythmias oc-
curred in 26% and in 22%, respectively, of the patients receiving metoprolol or carvedilol (HR: 0.80 [95% CI:
0.63 to 1.00], p  0.050). General use of beta-blockers and adherence in this study was high, and a clear dose-
dependent relationship was found in carvedilol, but not in metoprolol.
Conclusions In HF patients in New York Heart Association functional class I and II and with wide QRS complexes, carvedilol
was associated with a 30% reduction in hospitalizations for HF or death when compared with metoprolol. A
novel beneficial and synergistic effect of carvedilol was seen in patients with CRT-D and LBBB. Furthermore, we
found a pronounced dose-dependent relationship in carvedilol, but not in metoprolol. (MADIT-CRT: Multicenter
Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy; NCT00180271) (J Am Coll
Cardiol 2013;61:1518–26) © 2013 by the American College of Cardiology FoundationCardiac resynchronization therapy (CRT) has emerged as
an important device-based therapy for selected patients with
systolic heart failure (HF). Landmark clinical trials have
demonstrated the efficacy of CRT in patients with mild or
advanced HF symptoms despite optimal pharmacological
therapy (1–5). Optimal pharmacological therapy is consid-
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beta-blockers (BBs) in particular have been proven to
improve quality of life and reduce mortality in large popu-
lations of patients with systolic HF (7–9).
Presently, metoprolol and carvedilol are the BBs most often
used in the management of patients with HF, and the choice
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April 9, 2013:1518–26 Metoprolol and Carvedilol in Heart Failureof drug is left to the discretion of the physician because both
drugs have a class IA indication (10,11).
The COMET (Carvedilol or Metoprolol European Trial)
investigated the efficacy of metoprolol tartrate and carvedilol in
patients with moderate-to-severe HF, showing risk reduction
in cardiovascular mortality favoring carvedilol (7). Unfortu-
nately, no comparative randomized study has been done on
metoprolol succinate, the metoprolol salt proven in
MERIT-HF (Multicenter Automatic Defibrillator Implanta-
tion Trial With Cardiac Resynchronization Therapy) (9) to
educe mortality in HF patients, but indications that major
ifferences reside in these 2 widely used BBs remain. Further-
ore, numerous studies have shown that HF patients have
ifficulties reaching optimal BB doses, and therefore, the risk
eduction may not be as pronounced in real life as in the
andomized controlled trials.
The current information on BB therapy in HF patients
ith CRT devices is sparse.
Heywood et al. (12) found that patients with implantable
ardioverter-defibrillator (ICD) or cardiac resynchroniza-
ion therapy with an ICD (CRT-D) device were more likely
o be treated with target doses of BBs than those without a
evice and that absence of BBs is associated with poor
utcome (13). Furthermore, a small study has retrospec-
ively investigated the effect of carvedilol and metoprolol in
RT patients with HF and New York Heart Association
NYHA) functional class III to IV (14) and found no
ignificant difference in all-cause mortality between the 2
Bs. To our knowledge, no study has investigated the
ffects of metoprolol versus carvedilol in NYHA functional
lass I to II HF patients with CRT-D or ICD devices.
The MADIT-CRT study evaluated the effect of CRT-D
ersus ICD-only in relatively asymptomatic patients (NYHA
unctional class I to II) with a low ejection fraction and wide
RS complex; BBs were well used in this study (93%).
The aim of this study was to evaluate the effect of
etoprolol and carvedilol in HF patients receiving CRT-D
r ICD therapy in the MADIT-CRT trial.
ethods
ADIT-CRT. The protocol and primary article of the
ADIT-CRT study have previously been published (3,15).
The study included 1,820 patients with left ventricular
jection fraction (LVEF) 30%, QRS duration 130 ms,
nd ischemic cardiomyopathy NYHA functional class I or
I or nonischemic cardiomyopathy NYHA functional class
I. Patients were enrolled from 110 centers in Europe,
anada, and the United States and randomized in a 3:2
ashion for CRT-D or ICD devices. Patients were excluded
f they had atrial fibrillation at enrollment, whereas prior
istory of atrial fibrillation was not an exclusion criterion.
Patients had to be on optimal pharmacotherapy in accor-
ance with HF guidelines (6). However, the choice of BBs
nd other HF therapy was left to the discretion of the
mplanting and/or treating physician.The study was conducted in
he period from December 22,
004 through June 24, 2009, at
hich time the study was stopped
y recommendation of the safety
onitoring board. Extended
ollow-up was conducted until
eptember 10, 2010.
opulation. The MADIT-CRT
study included 1,820 patients with
1,089 patients in the CRT-D arm
and 731 patients in the ICD-arm.
Patients who received other
BBs than metoprolol or carve-
dilol or who did not receive any
BBs (n  275) and patients who
for some reason never received an
ICD or CRT-D (n  30) were
excluded from the baseline char-
acteristics shown in Table 1. Pa-
tients who received no BB or
received other types of BBs than
metoprolol or carvedilol at en-
rollment but changed to meto-
prolol or carvedilol during the
course of the study were included
in a time-dependent fashion. All
analyses were on an intention-to-
treat basis, and device crossovers were not considered.
Sensitivity analyses were conducted on crossovers of ICD or
CRT-D devices, which did not change the results.
Medication and doses. All medication, including type of
BB and the doses were recorded on patients at baseline and
clinical follow-up at 1 month and then at 3-month intervals
until the termination of the trial.
The individual dose was calculated as the baseline dose
divided by the patient’s weight, thereby yielding precise
estimates on the dose distribution in quartiles. All ac-
counted doses of metoprolol are metoprolol succinate or
recalculated doses from metoprolol tartrate.
Device programming and interrogation. The institu-
tional review board approved the protocol at each partici-
pating organization, and each patient provided written
informed consent before enrollment. Commercially avail-
able devices from Boston Scientific were used in this trial;
programming has been described in the pre-specified pro-
tocol (15). All devices were interrogated 1 month after
enrollment and thereafter every 3 months and after the
occurrence of any device therapy. All interrogation discs
were sent to an independent core laboratory for final
adjudication and interpretation. Device therapy was adjudi-
cated into pre-defined categories and, on the basis of these,
categorized as appropriate or inappropriate. The ventricular
tachycardia (VT) zone was set at 180 beats/min. VT was
Abbreviations
and Acronyms
BB  beta-blocker
CABG  coronary artery
bypass graft
CI  confidence interval
CRT  cardiac
resynchronization therapy
CRT-D  cardiac
resynchronization therapy
with implantable
cardioverter-defibrillator
HF  heart failure
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
IQR  interquartile range
LBBB  left bundle branch
block
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Association
VF  ventricular fibrillation
VT  ventricular
tachycardiadefined as ventricular rates up to 250 beats/min; ventricular
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Metoprolol and Carvedilol in Heart Failure April 9, 2013:1518–26Baseline CharacteristicsTable 1 Baseline Characteristics
Clinical Characteristics
Metoprolol
(n  438 [29.9%])
Carvedilol
(n  1,077 [71.1%]) p Value
Female 91 (21) 309 (29) 0.002
CRT-D–assigned treatment 275 (63) 637 (59) 0.190
Age at enrollment, yrs 65.0 10.3 63.5 11.0 0.013
Cardiac history
Ischemic NYHA functional class I 80 (18) 119 (11) <0.001
Ischemic NYHA functional class II 208 (47) 393 (36) <0.001
Non-ischemic NYHA functional class II 150 (34) 565 (52) <0.001
Hospitalization in prior year 224 (53) 464 (43) 0.001
Prior hospitalization for heart failure 168 (39) 413 (39) 0.860
Prior coronary-bypass surgery 147 (34) 264 (25) <0.001
Cerebrovascular accident 26 (6) 69 (6) 0.725
Diabetes 131 (30) 314 (29) 0.758
Hypertension 303 (69) 659 (61) 0.003
Prior non-CABG revascularization 140 (32) 262 (24) 0.002
Prior MI 226 (53) 393 (37) <.001
Non-U.S. implanting center 137 (31) 275 (26) 0.023
Previously smoked 226 (52) 550 (52) 0.942
Past atrial arrhythmias 52 (12) 109 (10) 0.341
Past ventricular arrhythmias 37 (9) 60 (6) 0.042
Medications
Antiarrhythmic agents, including amiodarone and sotalol 35 (8) 71 (7) 0.333
ACE inhibitor or ARB 419 (96) 1,034 (96) 0.758
Aldosterone antagonist 136 (31) 365 (34) 0.287
Calcium channel blocker 46 (11) 62 (6) 0.001
Digitalis 111 (25) 303 (28) 0.269
Diuretic 293 (67) 734 (68) 0.635
Statins 306 (70) 706 (66) 0.106
Thrombolytic excluding aspirin 90 (21) 192 (18) 0.217
Clinical characteristics at enrollment
QRS duration, ms 156.5 18.7 158.4 19.9 0.122
LBBB 302 (69) 780 (72) 0.167
RBBB 64 (15) 113 (11) 0.024
Heart rate, beats/min 67.8 11.5 67.7 10.2 0.891
Heart rate 80 beats/min 68 (16) 142 (13) 0.239
BMI, kg/m2 29.2 5.6 28.7 5.3 0.145
BUN, mg/dl 21.6 9.1 21.2 8.8 0.449
Creatinine, mg/dl 1.18 0.33 1.14 0.32 0.029
BNP level 117.0 131.5 125.1 170.4 0.147
Systolic blood pressure, mm Hg 123.8 17.5 121.7 17.0 0.024
Systolic blood pressure 140 mm Hg 90 (21) 166 (16) 0.014
Diastolic blood pressure, mm Hg 71.8 10.3 71.4 10.3 0.328
Diastolic blood pressure 80 mm Hg 63 (15) 162 (15) 0.768
Echocardiographic characteristics at enrollment
EF, % 23.9 5.2 23.6 5.3 0.333
LVEDV, ml 249.0 64.7 248.4 62.0 0.806
LVESV, ml 177.3 52.0 177.3 50.1 0.976
LAV, ml 92.8 21.3 93.6 22.1 0.587
Outcomes
Hospitalization for heart failure or death from any cause 132 (30) 243 (23)
Hospitalization for heart failure 115 (26) 205 (19)
Death from any cause 48 (11) 104 (10)
Ventricular tachycardia or fibrillation 115 (26) 241 (22)
Values are n (%) and mean  SD. p Values in bold are statistically significant.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; BMI  body mass index; BNP  B-type natriuretic peptide; BUN 
blood urea nitrogen; CABG coronary artery bypass graft; CRT-D cardiac resynchronization therapy with an implantable cardioverter-defibrillator;
EF  ejection fraction; LAV  left atrial volume; LBBB  left bundle branch block; LVEDV  left ventricular end-diastolic volume; LVESV  left
ventricular end-systolic volume; MI  myocardial infarction; NYHA  New York Heart Association; RBBB  right bundle branch block.
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April 9, 2013:1518–26 Metoprolol and Carvedilol in Heart Failurefibrillation (VF) was defined as ventricular rates faster than
250 beats/min with disorganized ventricular electrograms.
Endpoints. The primary endpoint of the present study was
efined as death from any cause or nonfatal HF events,
hichever came first. The diagnosis of HF, which required
ymptoms consistent with congestive HF and responsive to
econgestive therapy, was independently adjudicated by a
ortality committee unaware of study group assignments.
he pre-specified criteria have been described previously
15). The mode of death was adjudicated by the mortality
ommittee with the modified Hinkle-Thaler classification
16). The secondary endpoint was first occurrence of appro-
riate therapy for VF or VT as defined in the previous text.
tatistics. Patients were divided into 2 groups based on
their use of metoprolol or carvedilol, and their baseline
characteristics were compared using the chi-square test or
the Wilcoxon rank sum test, where appropriate.
Cox proportional hazard regression was used to compare
models with variables for BB therapy type use at baseline
with models that incorporated time-dependent covariates
for metoprolol or carvedilol. Two models were used, de-
pending on the endpoint. In the HF/death model, adjust-
ment was made for CRT-D treatment, left bundle branch
block (LBBB), CRT-D–LBBB treatment interaction, cre-
atinine level, hospitalization in prior year to enrollment, age,
ischemic etiology, LVEF, NYHA functional class, and the
use of other BBs or no BBs.
In the VT/VF model, we adjusted for CRT-D treatment,
LBBB, CRT-D–LBBB treatment interaction, age, LVEF,
female sex, non-U.S. centers, systolic blood pressure, prior
myocardial infarction, prior non-coronary artery bypass
graft (CABG) revascularization, prior ventricular arrhyth-
mias, and the use of other BBs or no BBs.
When specific subgroups were analyzed, these models
were modified omitting the variable investigated.
Time-dependent analysis. BB therapy was assessed in the
multivariate model in a time-dependent manner (i.e., by
incorporating in the Cox model variables for each patient
that identified the effect of each follow-up period “on” and
“off” BB therapy during the trial). The value of time-
dependent BB therapy covariates in predicting the risk of
various endpoints for the 2 treatment arms was estimated
using interaction terms.
Univariate and multivariate Cox proportional hazard regres-
sion analyses were performed for the primary endpoint of
HF/death and the secondary endpoint of VT/VF. In the
multivariate model, we adjusted for relevant variables that met
2 criteria. First, they needed to vary significantly between the 2
BB therapy types at baseline, and second, they were found to
be significantly predictive of the endpoint using stepwise
selection, with limits for entry into the model at a significance
level of 0.05. These potential confounders were adjusted for in
the multivariate Cox model.
Additionally, we carried out a propensity score—adjusted
Cox proportional hazards regression analysis. We quantified
a propensity score for the likelihood of receiving metoprolol dat baseline by multivariate logistic regression analysis using
the pool of baseline covariates and the stepwise procedure to
include only the statistical significant predictors. The pro-
pensity score adjustment compensates for clinical decisions
affecting the choice of beta-blocker prior to enrollment in
the study. The logistic regression analysis found four cova-
riates associated with a higher likelihood of receiving
metoprolol at baseline; age above 65 years, ischemic heart
failure etiology, prior hospitalization, and higher weight.
Hazard ratios (HRs) with their 95% confidence intervals
(CIs) and 2-sided p values are reported. The cumulative
probability of HF or death and VT/VF were displayed by
the method of Kaplan-Meier using the log-rank test to
compare cumulative events. A 2-tailed p value below 0.05
was considered statistically significant.
Analyses were performed using SAS statistical system
version 9.3 (SAS Institute, Cary, North Carolina).
Results
Clinical characteristics. The clinical characteristics of the
1,515 patients who received either metoprolol or carvedilol
are presented in Table 1. In short, patients receiving
metoprolol were more often male, marginally older, had
more ischemic cardiomyopathy, were more likely to be
enrolled at a non-U.S. center, and had a higher frequency of
prior myocardial infarctions, hypertension, and past ventric-
ular arrhythmias than patients receiving carvedilol.
During a mean follow-up period of 3.4  1.1 years, the
rimary endpoint of hospitalization for HF or death from
ny cause (whichever came first) occurred in 132 patients
30%) on metoprolol and in 243 patients (23%) on carve-
ilol. This endpoint included 48 (11%) and 104 (10%)
eaths in the 2 groups, respectively. The secondary endpoint
f ventricular arrhythmias and VT occurred in 115 patients
26%) and 241 patients (22%) receiving either metoprolol or
arvedilol, respectively. Kaplan-Meier estimates of the pri-
ary outcome in the 2 study groups are shown in Figure 1.
rimary and secondary endpoints. In the univariate Cox
nalysis, there was a significant association between the use
f carvedilol and a reduction in HF or death compared with
etoprolol (HR: 0.72, 95% CI: 0.58 to 0.89, p  0.002),
hich was confirmed in the multivariate analysis as shown
n Table 2. The relative risk reduction after adjusting for
elevant confounders was 30%, which was driven primarily
y a reduction in hospitalizations for HF, primarily in the
RT-D–treated part of the study. Univariate analysis in
he event of VT/VF revealed a trend in difference
etween metoprolol and carvedilol (HR: 0.83, 95% CI:
.66 to 1.03, p  0.090) as shown in Figure 2. In the
ultivariate analysis, however (Table 2), a 20% relative
isk reduction in VT/VF was found significantly associ-
ted with the use of carvedilol.
RT-D ARM. In the CRT-D arm of the population, the
ifference in risk of HF/death between the two BBs
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Metoprolol and Carvedilol in Heart Failure April 9, 2013:1518–26persisted and was even more pronounced in univariate (HR:
0.68, 95% CI: 0.51 to 0.91, p  0.010) as well as in
multivariate analyses, presented in Table 2. The relationship
and direct comparison with the ICD group is depicted in
Figure 3. No significant difference was found in the second-
ary endpoint of VT and VF in the CRT arm of the study,
but a trend was evident (HR: 0.74, 95% CI: 0.54 to 1.01, p 
0.054) in univariate as well as multivariate analyses (Table 2).
CRT-D AND LBBB. Selecting the subgroup of patients receiv-
ng CRT-D treatment who had LBBB, there was a signif-
cant beneficial effect in patients receiving carvedilol (HR:
Figure 1 Kaplan-Meier Estimates of the Probability of Hospitali
A significant difference was found in the estimate of probability of heart failure (HF
those receiving carvedilol. Unadjusted p value  0.002.
Time-Dependent Multivariate Cox Regression Analysis on EndpointTable 2 Time-Dependent Multivariate Cox Regression Analysis
Study Population
and Subgroups
HF/Death
HR
Carvedilol:Metoprolol 95% CI p Value
MADIT-CRT 0.70 0.57–0.87 0.001
CRT-D 0.61 0.46–0.82 0.001
ICD 0.81 0.59–1.11 0.191
CRT-D and LBBB 0.51 0.35–0.76 0.001
CRT-D and non-LBBB 0.79 0.51–1.23 0.290
ICD and LBBB 0.96 0.66–1.39 0.830
ICD and non-LBBB 0.55 0.30–1.00 0.048
LBBB 0.73 0.56–0.95 0.021
Non-LBBB 0.64 0.45–0.91 0.012
Heart failure (HF)/death model adjusted for CRT-D treatment, LBBB, CRT-D–LBBB treatment intera
class, and the use of other beta-blockers or no beta-blockers. VT/VF model adjusted for CRT-D trea
pressure, prior myocardial infarction, prior non-CABG revascularization, prior ventricular arrhythmia
these models were modified omitting the variable investigated.CI confidence interval; HR hazard ratio; ICD implantable cardioverter-defibrillator; MADIT-CRTM
ventricular fibrillation; VT  ventricular tachycardia; other abbreviations as in Table 1..58, 95% CI: 0.39 to 0.86, p  0.006) as compared with
etoprolol. Multivariate results in Table 2 show the inde-
endent and synergistic effect of carvedilol, CRT-D treat-
ent, and LBBB QRS morphology. Furthermore, when
omparing metoprolol and carvedilol in patients in this
ubgroup, there was a similar significant association between
he type of BB and the risk of ventricular arrhythmias,
ltimately favoring carvedilol. In Table 2, the overall rela-
ionship between outcome and LBBB is shown favoring
arvedilol, with a 49% relative reduction in HF/death
ompared with metoprolol among patients treated with a
RT-D device.
ns for HF or Death
ts between patients receiving metoprolol as compared with
paring Carvedilol With Metoprololndpoints Comparing Carvedilol With Metoprolol
VT/VF
action
alue
HR
Carvedilol:Metoprolol 95% CI p Value
Interaction
p Value
0.80 0.63–1.00 0.050
193 0.76 0.56–1.02 0.069 0.582
193 0.86 0.61–1.21 0.390 0.582
155 0.57 0.39–0.85 0.005 0.031
155 1.14 0.70–1.85 0.605 0.031
116 0.65 0.43–0.97 0.035 0.038
116 1.51 0.76–3.01 0.243 0.038
532 0.63 0.48–0.83 0.001 0.007
532 1.23 0.83–1.83 0.304 0.007
reatinine, hospitalization in prior year to enrollment, age, ischemic etiology, LVEF, NYHA functional
LBBB, CRT-D–LBBB treatment interaction, age, LVEF, female sex, non-U.S. centers, systolic blood
the use of other beta-blockers or no beta-blockers. Note: When specific subgroups were analyzed,zatio
) evens Comon E
Inter
p V
0.
0.
0.
0.
0.
0.
0.
0.
ction, c
tment,
s, andulticenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy; VF
m
p
w
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study on either hospitalization for HF, death, or VT/VF
between the 2 groups.
The propensity-scored analyses yielded nearly identical
results, as shown in the Online Appendix.
BB adherence and initial doses at baseline. The mean
dose of metoprolol at baseline was 66  48 mg, median 50
mg (interquartile range [IQR]: 25 to 100 mg), and the mean
Figure 2 Cumulative Probability of Ventricular Tachycardia or V
A nonsignificant association was found in the estimate of probability of ventricular arrhyt
This association was borderline significant in the multivariate analysis. Unadjusted p value
Figure 3 Kaplan-Meier Estimates of the Probability of Hospitali
Significant differences were found in the estimate of probability of heart failure (H
carvedilol, with wide differences depending on the type of device implanted. No di
cardioverter-defibrillator (ICD) with patients on metoprolol receiving cardiac resynch
BB  beta-blocker.dose of carvedilol at baseline was 18  13 mg, median 12.5
g (IQR: 6.25 to 25 mg), with recalculations to mean dose
er body weight of metoprolol of 0.75 mg/kg compared
ith 0.22 mg/kg of carvedilol (median: 0.60 mg/kg (IQR:
.38 to 0.98 mg/kg) and 0.18 (IQR: 0.09 to 0.29 mg/kg), in
he 2 groups, respectively.
From baseline to first change, the mean increase in dose
n metoprolol was 16  28 mg (n  146), while the mean
cular Fibrillation
between patients receiving metoprolol as compared with those receiving carvedilol.
9.
ns for HF or Death Comparing Device Group and BB Group
ts between patients receiving metoprolol as compared with those receiving
e was found comparing patients on carvedilol who received an implantable
tion therapy with an ICD (CRT-D) treatment. Unadjusted p value 0.001.entri
hmias
 0.0zatio
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Metoprolol and Carvedilol in Heart Failure April 9, 2013:1518–26change in dose on carvedilol was 13  11 mg (n  947).
Only small differences were seen in the BB adherence or
changes in doses through the rest of the study, 19 patients
changed dosages of metoprolol and 38 patients changed
dose of carvedilol. The mean change in dose of metoprolol
was 2  39 mg and 4  12 mg in carvedilol, quite
venly distributed in the CRT-D and ICD populations.
verall, 92 patients changed from one type to the other, of
hich 68 patients changed from metoprolol to carvedilol,
nd 24 patients changed from carvedilol to metoprolol.
hese changes are taken into account in the time-
ependent analyses. In total, 12% of those on metoprolol
sed the metoprolol tartrate salt, and these doses have been
ecalculated to metoprolol succinate equivalents.
Kaplan-Meier estimates of the dose relationship and
rimary endpoint as selected by the values above the 3rd
uartile (0.29 mg/kg and 0.98 mg/kg) in carvedilol and
etoprolol are depicted in Figure 4 presenting differences in
the outcome. This dose relationship of carvedilol was
further substantiated in CRT-D and LBBB patients, again
in a synergistic fashion.
Discussion
To our knowledge this is the first study to investigate and
compare metoprolol with carvedilol in a setting of relatively
asymptomatic HF patients with low EF and wide QRS
receiving either a CRT-D or ICD device.
The primary composite endpoint of hospitalization for
HF and death showed a marked event reduction in patients
Figure 4 Kaplan-Meier Estimates of the Probability of Hospitali
Death Comparing Patients With Metoprolol and Carve
Significant differences were found in the estimate of probability of heart failure (H
carvedilol depending on dose as defined by values above and below the 3rd quart
the 3rd quartile is visualized for carvedilol, whereas no dose-dependent relatio
Figure 3.treated with carvedilol, which was primarily driven by asynergistic effect of carvedilol and CRT-D treatment in the
population with LBBB QRS morphology. This major
difference in hospitalizations for HF has not previously been
described in the setting of NYHA functional class I and II
patients and the novel association and synergistic effect of
CRT-D treatment and carvedilol, primarily in the setting of
LBBB patients, requires further attention.
We found a borderline significant 20% relative risk
reduction between carvedilol and metoprolol on our
secondary endpoint of VT or VF, but further attenuated
in the subgroup of LBBB patients and a marked and
significant effect in the CRT-D and LBBB subset. The
effect of carvedilol, particularly in LBBB and CRT-D–
treated patients, thus efficiently reduces the risk of
ventricular arrhythmias.
BB adherence and therapy in the MADIT-CRT
study. Are the results all about dosage? Mean carvedilol
doses in MADIT-CRT were 18 13 mg, mean metoprolol
doses were 64 47 mg, which is comparable to real-life doses
administered to HF patients in the clinical setting, although
somewhat lower than the doses in the previous randomized
clinical drug trials. In OPTIMIZE-HF (Organized Program
to Initiate Lifesaving Treatment in Hospitalized Patients
with Heart Failure) (17), the mean dose of carvedilol was 22
mg and the mean dose of metoprolol was 69 mg in patients
who had systolic HF. The COMET trial mean dose was 42
mg and 128 mg in carvedilol and metoprolol (recalculated
from metoprolol-tartrate), respectively, whereas in the
COPERNICUS (Carvedilol Prospective Randomized Cu-
ns for HF or
Depending on Doses
ts between patients receiving metoprolol as compared with those receiving
(mg/kg). Significant difference on outcome between values higher or lower than
was evident for metoprolol. Unadjusted p value  0.003. Abbreviations as inzatio
dilol
F) even
ile (Q)
nshipmulative Survival) trial, the mean dose of carvedilol was 45 mg.
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So, comparing the equivalent mean doses of carvedilol to
metoprolol, the drug comparison is reasonable and also in line
with achievable doses in clinical practice. However, when
converting the doses of metoprolol into doses of carvedilol
equivalents, there was a somewhat small difference in mean
dosage. The mean carvedilol equivalent in the metoprolol
group was 16  12 mg, which was a small, but significant,
difference (p 0.004) compared with carvedilol (18 13 mg).
We do not believe this small difference in baseline mean
carvedilol equivalents account for the major differences seen.
In our subanalysis, we did not find a decrease in risk
associated with a higher dose of metoprolol, whereas there
was a clear dose-dependent relationship of carvedilol on
HF/death.
The use of BB in MADIT-CRT was high (93% at
enrollment), compared with 68% in the COMPANION
(Comparison of Medical Therapy, Pacing, and Defibrilla-
tion in Chronic Heart Failure) trial, 70% in CARE-HF
(Cardiac Resynchronization–Heart Failure) (18), and about
85% in IMPROVE HF (Registry to Improve the Use of
Evidence-Based Heart Failure Therapies in the Outpatient
Setting) (12). MADIT-CRT patients were eligible when
they had been appropriately treated with a BB at a thera-
peutic dose for the last 3 months, and had been stable for at
least 1 month before enrollment. The choice of selective or
nonselective BB was left to the physician’s discretion. Thus,
no optimal target dose was given in the enrollment criteria.
In OPTIMIZE-HF, only 17.5% and 7.9% received target
doses of carvedilol and metoprolol, respectively (17). In
MADIT-CRT, maximum baseline doses of carvedilol (50
mg) and metoprolol (200 mg) were given in 55 (5.1%) and
23 patients (5.3%), respectively.
There remains no definitive evidence of a dose-response
relationship between BB therapy and outcomes in a ran-
domized trial, and a recent meta-analysis of 23 BB trials
failed to show an association between BB dose and survival
benefit in HF (19) and that heart rate reduction in itself
yields the survival benefit of BBs in HF. However, a recent
study from HF-ACTION (Heart Failure: A Controlled
Trial Investigating Outcomes of Exercise Training) showed
a linear correlation between up to 50 mg of daily dose of
carvedilol in ambulatory patients and significantly lower
rates of all-cause death and all-cause hospitalization (20).
Our study was not designed to address the relationship of
dose benefit; however, it does clearly raise the question of
the achievability of currently recommended BB dose targets.
We speculate that low baseline resting heart rates in our
study indicate that the patients generally were well titrated
at baseline and that the rate may have contributed to a
relatively low dose in both metoprolol and carvedilol com-
pared with the BB dosage in clinical trials. The mean heart
rate in the MADIT-CRT was 68 beats/min, suggesting a
reasonable amount of beta blockage, and importantly, no
difference was found between the 2 groups of carvedilol and
metoprolol.So what causes patients on metoprolol to be hospitalized
more often for HF than patients on carvedilol? It is not
evident from shocks given for appropriate therapy; however,
a borderline significant trend supported less VT/VF in the
patients receiving carvedilol. In the COMET trial, the
primary endpoint was driven by cardiovascular deaths,
whereas our findings, in a lower-risk population than the
COMET population, indicate that carvedilol also reduces
hospitalizations for HF with a 30% relative risk reduction,
with further benefit in CRT-D and LBBB subgroups. As
noted, unfortunately, COMET was designed with the use
of metoprolol tartrate instead of metoprolol succinate,
whereas metoprolol used in our study consists of both salts
as in real life.
BBs and CRT may have complementary salutary effects
as shown by Voigt et al. (13), and our results show that
carvedilol in particular is associated with reduction in the
rate of hospitalizations for HF, especially in CRT patients
with LBBB QRS morphology.
The conclusion in the COMET trial was that the benefit
of carvedilol is driven by a reduction in mortality. In
MADIT-CRT, the overall mortality rate is markedly lower
than the mortality rates in the clinical trials MERIT-HF,
COMET, and CIBIS (Cardiac Insufficiency Bisoprolol
Study), with a yearly mortality rate of 3% compared with 7%
to 10%. Extrapolating the results, it seems that carvedilol is
superior to metoprolol in terms of cardiovascular death,
supported by risk reductions in our subgroups of VT/VF,
but most definitely in terms of HF hospitalizations in our
patients. The clinical data and evidence supporting carve-
dilol in favor of metoprolol now exceed NYHA functional
class III to IV and cardiovascular death extending it to
NYHA functional class I to II and HF hospitalizations in
ischemic and nonischemic cardiomyopathy with wide QRS
complexes. Also it seems evident that there are synergistic
effects of carvedilol and CRT-D treatment, which again is
powered with increased doses of carvedilol. The use of
metoprolol succinate at the target dose of 200 mg/day
should, however, still be justified based on the MERIT-HF
data. The definitive head-to-head comparison of carvedilol
and metoprolol succinate at the doses proven to reduce
mortality remains to be done, but we find this is a relevant
comparison on “real-life” obtainable doses in mild symp-
tomatic HF patients.
Study limitations. One limitation is that the dosages of
carvedilol and metoprolol were lower than generally
achieved in the clinical randomized trials. Another limita-
tion was that although multivariate analysis showed that
carvedilol was superior to metoprolol when taking many
confounders into consideration, it was not a prospective
randomized trial comparing these drugs, and other con-
founders not included in the analyses may have biased our
results. However, our findings are consistent with the
overall results of the COMET trial.
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In HF patients in NYHA functional class I and II, with low
ejection fraction, wide QRS, and either a CRT-D or ICD
device therapy, carvedilol proved superior in terms of a 30%
reduction in hospitalizations for HF or death compared
with metoprolol. A beneficial and synergistic effect of
carvedilol was seen in patients with CRT-D and LBBB
QRS morphology with a 49% reduction in HF/death
compared with metoprolol. We found similar reductions in
risk of ventricular arrhythmias associated with the use of
carvedilol. Furthermore, we found a pronounced dosage-
dependent relationship between outcome and dose in carve-
dilol, which was not found in metoprolol-treated patients.
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